Treventis attends the 2nd Neuromuscular Drug Development Summit (NMD)

CEO Christopher Barden attended the NMD Summit in Boston, Massachusetts, where he spoke with therapeutic and diagnostic companies that are working in the areas of amyotrophic lateral sclerosis (ALS), spinal muscular atrophy, and muscular dystrophy, as well as other rare diseases with neuromuscular symptoms. This year’s summit surveyed biomarkers, clinically meaningful endpoints, and regulatory challenges and opportunities in these diseases.

Treventis has an active program in discovery of compounds that affect the misfolding of proteins implicated in ALS.

Share this page

#pf-body .pf-caption img.blockImage { margin: 0!important; float: none; } #pf-body a.elementor-icon, #pf-body a.skip-link{display:none!important;} /*#pf-content {max-width:100%!important}*/ #pf-content img.mediumImage, #pf-content figure.mediumImage { margin-left: auto!important; margin-right: auto!important; clear: both!important; float: none!important; display: block!important; }